Product Details
| Product Name:
Rimtuzalcap |
CAS No.:
2167246-24-2 |
| Purity:
99.54% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | Rimtuzalcap |
| Description | Rimtuzalcap (CAD-1883) (CAD-1883), a pioneering selective positive allosteric modulator of small-conductance calcium-activated potassium channels (SK channels), is employed in the study of movement disorders such as spinocerebellar ataxia (SCA) and essential tremor (ET). |
| In vitro | Rimtuzalcap (Compound 1), a small-molecule modulator of potassium ion channels, exhibits significant therapeutic promise for addressing a range of diseases. These diseases are marked either by the dysfunction of potassium ion channels or by other factors affecting these channels[1]. |
| In vivo | Rimtuzalcap (CAD-1883) effectively decreases Purkinje cell firing rate by about 40%, aligning with its expected therapeutic action of enhancing SK channel activity through positive allosteric modulation. When applied in sequence, either 1 or 3 μM of CAD-1883 can partially reverse the augmented coefficient of variation in interspike intervals noted in cerebellar slices from 11-month-old spinocerebellar ataxia-2 58Q mice[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 250 mg/mL (660.64 mM), Sonication is recommended.
|
| Keywords | KcsA | movement | small-conductance | channels | CAD1883 | CAD 1883 | SK channels | tremor | Potassium Channel | essential | inhibit | spinocerebellar | potassium | ataxia | Rimtuzalcap | SCA | Inhibitor | disorders | calcium-activated |
| Inhibitors Related | Minoxidil sulfate | Quinine | (±)-Naringenin | Tolbutamide | Tetraethylammonium bromide | Halothane | Butamben | Tetraethylammonium chloride | Cloperastine hydrochloride | 2,2,2-Trichloroethanol | Chlorzoxazone | Indapamide |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Neuroprotective Compound Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
CAS:1996629-79-8
$89.00 / 1mg
-
CAS:639-14-5
$136.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States